Company Description
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation.
The company was incorporated in 1996 and is headquartered in San Rafael, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 23, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,401 |
| CEO | Alexander Hardy |
Contact Details
Address: 770 Lindaro Street San Rafael, California 94901 United States | |
| Phone | 415 506 6700 |
| Website | biomarin.com |
Stock Details
| Ticker Symbol | BMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001048477 |
| CUSIP Number | 09061G101 |
| ISIN Number | US09061G1013 |
| Employer ID | 68-0397820 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Hardy | President, Chief Executive Officer and Director |
| Brian R. Mueller | Chief Financial Officer and Executive Vice President |
| Dr. C. Greg Guyer Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Henry J. Fuchs M.D., Ph.D. | Advisor |
| Erin Burkhart | Group Vice President and Chief Accounting Officer |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer and Senior Vice President of Research and Early Development |
| Traci McCarty | Group Vice President of Investor Relations |
| George Eric Davis | Executive Vice President, Chief Legal Officer, General Counsel and Secretary |
| Humaira Serajuddin | Senior Vice President and Chief Marketing Officer |
| Amy Wireman | Executive Vice President and Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 3, 2024 | UPLOAD | Filing |
| Sep 30, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 24, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 8-K | Current Report |
| Sep 2, 2024 | UPLOAD | Filing |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 144 | Filing |